The global viral inactivation market size was valued at USD 1.8 billion in 2016 and is expected to witness a CAGR of 12.5% during the forecast period. The global rise in the number of pharmaceutical and biopharmaceutical companies, increasing investment in the life sciences sector, rise in the number of drug launches & approvals, increase in funding by government for the development of pharmaceutical and biopharmaceutical industries are some of the major factors propelling the growth of the market.
The global rise in the number of chronic diseases like cancer, diabetes, autoimmune disorders, and other diseases has led to an increase in healthcare expenditure. An increase in healthcare spending is mainly required to devise and develop new & enhanced therapies to tackle the rise in these diseases. Increasing R&D innovation, drug discoveries, and FDA approvals leading to commercialization of new drugs is resulting in the growth of the market.
Viral inactivation market revenue by product, 2014 - 2025 (USD million)
In recent years, a huge number of companies and other government bodies have invested heavily in the development of the life sciences segment. This has led to an overall increase in the number of new and alternative therapies for the treatment of diseases, such as stem cell therapy and cellular & gene therapy. Viral inactivation is a crucial process that is mandatory in the production of these products to prevent contamination and prevent any fatalities after human consumption.
Viral inactivation is a vital part of the viral clearance process that is mandatory for any drug development process. Regulatory authorities such as FDA have intensified the need for viral inactivation in various applications such as cellular & gene therapy, vaccines, therapeutics, tissue & tissue products, stem cell products, and blood & blood products. This has allowed further growth of the market.
Based on the product, the market is categorized into kits & reagents, systems, and services. Kits and reagents accounted for the largest market share in the market due to their continuous usage by pharmaceutical and biopharmaceutical companies. Services are anticipated to grow at the highest rate owing to ease of management and specialized services offered by service providing companies.
With an increase in the number of pharmaceutical and biopharmaceutical companies and a rise in R&D spending for new drug development, the usage of kits and reagents has increased tremendously. Thus, owing to the increasing utilization of consumables, kits, and reagents in various end-use settings, it was the largest segment concerning the product in the market.
A wide range of instruments aid in the process of viral inactivation. For instance, FlexAct VI developed by Sartorius AG is a single-use technology that allows virus inactivation with the usage of low pH. The device is designed in a way to address the production capacity and tailored to adjust features like pH, pressure, temperature, pump speed, and fluid level.
Virus inactivation is a vital process in the drug manufacturing companies that require sterilization of the media before product finalization. Thus, a wide range of methods is provided as services by many Contract Research Organizations (CROs). All safety and quality standards are maintained at such facilities as they provide efficient virus inactivation and planning of further steps in the drug development process.
Based on application, the viral inactivation market is segmented into vaccines & therapeutics, stem cell products, blood & blood tissue products, tissue & tissue products, and cellular & gene therapy products. Vaccines & therapeutics is expected to grow at the fastest rate due to growth in biologics production and an increase in government funding for the promotion of usage of biologics to treat diseases. Increasing R&D innovation in various other applications such as stem cell research and cellular & gene therapy has also been significantly contributing to the growth of the market.
Stem cell products are procured from donors and the risk of contamination is high owing to the requirement of intense monitoring concerning viral inactivation. Stem cell research has been increasing rapidly in developed countries like the U.S. and other European countries. This increase has contributed largely to the growth of the segment. Stem cell research has been pursued largely to gain a deeper insight into human health and discover new ways to treat illnesses & diseases.
U.S viral inactivation market revenue by application, 2014 - 2025 (USD million)
With a global rise in the number of transplantation procedures, there has been an increase in tissue and tissue products. Since the risk of viral contamination from donors is very high, the need for viral inactivation in these products is tremendous. Most of the time, solvent detergent is a preferred choice of viral inactivation in these instances. Low pH is another method that is used for viral inactivation in blood tissue and tissue products.
In most cases, the sources of vaccines and therapeutics are mammalian cell cultures, bacteria, insect cell culture, plant cell culture, mice, humans, avian cell culture, and yeast (in some cases). Inactivation of viruses in these cases is an integral part of safety and assessment procedures, making the intended product safe for human usage. Thus, the growth of the market of viral inactivation has been significant owing to the consistent usage of viral inactivation products in applications, such as cellular & gene therapy, stem cell products, and tissue & tissue products.
Based on end-use, the viral inactivation industry is divided into pharmaceutical and biopharmaceutical companies, CROs, academic & research institutes, and others. Others include medical device companies, laboratories, and blood banks. Pharmaceutical and biopharmaceutical companies accounted for the largest share owing to an increased usage of these products for drug development and drug manufacturing. CROs provide customized services and efficient management of the entire viral inactivation process. Therefore, these are expected to gain considerable share during the forecast period.
The growth of pharmaceutical and biopharmaceutical companies has been immense over the past few decades. An increase in the amount of investment to find alternative therapies has increased the number of new drugs. With the introduction of biologics and other cellular & gene therapy products, the usage of viral inactivation products has been increasing in pharmaceutical and biopharmaceutical companies.
Stringent regulatory requirements for therapeutic agents ensure the safety of the product, for human use. Usage of techniques like solvent detergent, low pH, pasteurization, and other methods is found commonly in biopharmaceutical companies to ensure the safety of the product. Companies make use of single-use systems or bioreactors to perform these procedures and conduct viral inactivation.
CROs provide outsourcing services that aid in viral inactivation processes of pharmaceutical and biopharmaceutical companies. As they provide specific services as per the needs of the client, they are preferred over in house process management systems. A simplified process, ease of management, and availability of customized services are some of the major reasons responsible for the growth of CROs.
Some of the dominant players in the market are Sartorius AG, Merck KGaA, Parker Hannifin, Rad Source Technologies, Clean Cells, WuXi PharmaTech (Cayman) Inc., and Danaher. The market is highly fragmented with the presence of many large-, small-, and medium-scale players. These leading players face competition from local players.
The majority of the players are focusing on the development of new products. Mergers and acquisitions are frequently seen in the market resulting in a high degree of market consolidation. For instance, in August 2015, Danaher Corporation completed the acquisition of Pall Corporation, a leading provider of virus clearance products.
The base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, & MEA
U.S., Canada, UK, Germany, France, Italy, Spain, Japan, India, China, India, Brazil, Mexico, South Africa, Saudi Arabia
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global viral inactivation market based on product, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Kits and reagents
Application Outlook (Revenue, USD Million, 2014 - 2025)
Vaccines and Therapeutics
Stem Cell Products
Blood and Blood Products
Tissue/ Tissue Products
Cellular and Gene Therapy
End-Use Outlook (Revenue, USD Million, 2014 - 2025)
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Regional Outlook (Revenue, USD Million, 2014 - 2025)
The Middle East and Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.